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Central Nervous System (CNS)-related safety concerns are major contributors to delays and failure during
the development of new candidate drugs (CDs). CNS-related safety data on 141 small molecule CDs from
ﬁve pharmaceutical companies were analyzed to identify the concordance between rodent multi-
parameter neurofunctional assessments (Functional Observational Battery: FOB, or Irwin test: IT) and
the ﬁve most common adverse events (AEs) in Phase I clinical trials, namely headache, nausea, dizziness,
fatigue/somnolence and pain. In the context of this analysis, the FOB/IT did not predict the occurrence of
these particular AEs in man. For AEs such as headache, nausea, dizziness and pain the results are perhaps
unsurprising, as the FOB/IT were not originally designed to predict these AEs. More unexpected was that
the FOB/IT are not adequate for predicting ‘somnolence/fatigue’ nonclinically. In drug development, these
ﬁve most prevalent AEs are rarely responsible for delaying or stopping further progression of CDs. More
serious AEs that might stop CD development occurred at too low an incidence rate in our clinical dataset
to enable translational analysis.
© 2016 The Author(s). Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Attrition of candidate drugs due to adverse drug reactions (ADR)
associated with the central nervous system (CNS) is a majorkson).
novative Medicines and Early
Science Park, Milton Road,
l Development, Chemin du
r Inc. This is an open access article uconcern to pharmaceutical companies (Valentin and Hammond,
2008). Furthermore, undesirable side-effects on the nervous sys-
tem in humans have accounted for 10% of all drugs withdrawn from
sale during the period 1960e1999 (Fung et al., 2001). For this
reason, assessment of CNS safety is particularly important for all
new drug candidates. This is recognized by its inclusion within the
‘core battery’ (Tier I) assessment of vital organ functions in the
International Council on Harmonisation of Technical Requirements
for Registration of Pharmaceuticals For Human Use (ICH) S7A
guideline for Safety Pharmacology (ICHS7A, 2001). In particular, it
is stated that “Effects of the test substance on the central nervous
system should be assessed appropriately” and “For example, ander the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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priate test can be used”. The FOB/Irwin test batteries comprise a
range of tests in the rodent and have been evaluated across
different laboratories and companies and with multiple compound
classes. They are considered sensitive for detection of various
adverse effects on the nervous system in humans (Baird et al., 1997;
de Ron et al, 2015; Ewart et al., 2014; Igarashi et al., 1995; Irwin,
1968; Moscardo et al., 2007; Redfern et al. 2002, 2005).
There have been previous analyses to correlate nonclinical and
clinical adverse event ﬁndings. These are summarized in Table 1
and show a range of ADRs predicted by the rodent from 19% (van
Meer et al., 2012) to 57% (Igarashi et al., 1995). The majority of
these analyses (apart from (Olson et al., 2000) and (Ewart et al.,
2014) are based on published data. Olson and colleagues exam-
ined the strengths and weaknesses of animal studies to detect
human toxicity using data from 150 compounds based on a survey
of 12 pharmaceutical companies (Olson et al., 2000). The results
showed an overall concordance rate of 71% for rodent and non-
rodent species, combined with non-rodent species (predomi-
nantly dog) being predictive for 63% and rodent species for 43% of
human toxicity. Olson et al. (2000) showed that for neurological
effects, non-rodent datawere better correlated with adverse effects
in human than rodent data.
More recently, van Meer and colleagues retrospectively inves-
tigated whether animal studies that were part of the registration
ﬁle could have identiﬁed post-marketing serious adverse reactions
(SARs), and reported that animal studies were not sensitive enough
to predict these SARs, as only 19% were detected as true positive
outcomes (van Meer et al., 2012). Tamaki and colleagues have
recently published a stratiﬁed analysis on concordance between
non-clinical safety assessment and clinical ADRs (Tamaki et al.,
2013). This analysis demonstrates that 48% of ADRs were pre-
dicted based on animal toxicity studies and 30% of neurological
ADRs correlated with nonclinical studies. Finally, a recent review
suggested that the absence of toxicology ﬁndings in rat, mouse or
rabbit provided limited information regarding the likelihood of
toxicity in humans, while the presence of non-clinical toxicology
ﬁndings can predict human toxicity, albeit with marked variability
across compound classes (Bailey et al., 2014).
Most studies investigating the predictive value of animal studies
in drug development have either involved limited datasets in terms
of size and scope, have used incorrect statistical deﬁnitions or do
not take exposure-effect relationships into account (Matthews,
2008). Therefore, there is the need for an unbiased and compre-
hensive analysis, based on an objective framework including
comparative physiology and pharmacology of animal models and
human events. In order to develop such a framework, ﬁve phar-
maceutical companies collaborated with the Association of BritishTable 1
Publications providing evidence of good translation from rat FOB/Irwin to human for eff
Reference Number of
compounds
Dates Drug class descriptor No. ADRs
predicted b
rodent
Igarashi et al., 1995 J.
Tox. Sci.
104 1987
e1992
Multiple 57%
Olson et al., 2000 Reg.
Tox. Pharm.
150 Pre-
1999
Multiple 43%
van Meer et al., 2012
Reg. Tox. Pharm.
43 1999
e2010
Multiple 19%
Tamaki et al., 2013 J Tox.
Sci.
142 2001
e2010
Anticancer agents and
vaccines excluded
48%
Bailey et al., 2014
Altern. Lab. Anim.
2366 n/a Multiple (species
used ¼ dog
Ewart et al., 2014 Tox.
Sci.
113 Post-
2001
Cardiovascular (species
used ¼ dogPharmaceutical Industry (ABPI) to create the Animal Model
Framework (AMF) project (Valentin et al., 2009). The UK National
Centre for the Replacement, Reﬁnement and Reduction of Animals
in Research (NC3Rs) was the independent broker for anonymised
data-sharing and analysis for this study. The AMF consortia brings
together scientists from different pharmaceutical companies to
share data and assess the translation of nonclinical endpoints for
speciﬁc clinical outcomes, with the intention of improving safety
related attrition in the drug discovery arena (Valentin et al., 2009).
One recent example assessed the predictive validity of nonclinical
large animal cardiovascular assessments for ﬁrst-in-human (FIH)
cardiovascular outcome, highlighting where the nonclinical models
were strongest and where improvements could be made (Ewart
et al., 2014).
As the primary purpose of nonclinical safety pharmacology
studies is to protect Phase I volunteers (ICHS7A, 2001), and as Phase
I would provide a larger dataset (in terms of number of compounds
progressing) than subsequent phases, we assessed the concordance
between nonclinical data on CNS functions with common Phase I
adverse events (AEs). The most frequent clinical AEs reported
within our dataset were headache, nausea, dizziness, fatigue/
somnolence and pain and therefore provide a sufﬁciently large
dataset to permit meaningful statistical comparisons. The AEs
analyzed are considered to potentially represent both direct and
indirect drug effects on the CNS and have a plausible nonclinical
correlate in the neurobehavioral assessment. It is important to note
that while the perception of nausea, pain or fatigue requires the
CNS, the cause of these AEs may be a direct effect of the candidate
drugs on the gastrointestinal system or skeletal muscles,
respectively.
The collaborative, data-sharing approach strives to provide a
consistent data set across different companies. Given that each
stage of the drug discovery process typically informs the subse-
quent stage (Redfern et al., 2002), and that safety pharmacology
data from young healthy male animals was being collated to
predict effects in young healthy male human volunteers, the
expectation was that the FIH-enabling CNS assessment in rodents
should be predictive of commonly reported AEs in the FIH study.
Furthermore, the study designs were considered reasonably
consistent across companies, thus facilitating the pooling of data.
The AMF aims to use the evidence and data analysis to provide a
quantitative assessment of translational value. The use of such a
framework should facilitate key decision making within industry,
enable the critical assessment of the value of existing models,
and ultimately facilitate clinical trial design, decision making,
and potentially reduce attrition rate of CDs due to AEs in the
clinic.ects related to ‘somnolence’ or ‘fatigue’.
y
Additional information
Data from Japanese Pharmaceutical Manufacturers Association
Unpublished company data.
Non-rodent data (Dog): predictive of 63% of ADRs.
Published data. Assessment of post-marketing serious adverse reactions.
Published data. 30% when only neurological batteries considered
)
Published data. Positive likelihood ratio ¼ 28 (range 4.7e548.7).
)
Unpublished company data. Concordance for drug effects on dog QTc
interval (sensitivity: 88% and speciﬁcity: 76%).
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2.1. Data collection
Each company provided rodent nonclinical data from either a
FOB or an Irwin study (referred to subsequently as the neuro-
functional assessment or ‘FOB/IT’) including mean free plasma drug
exposure data (free Cmax) and clinical data on side effects reported
in Phase I clinical trials, including human free Cmax data, for each
dose level tested. Selection of compounds was randomly based on
availability and ease of access from any compounds that progressed
to FIH testing between 2000 and 2011, in order to mitigate bias
from a scientiﬁc or business perspective. The year 2000 was
selected as the start date since ICH-S7A was implemented in that
year, and the year 2011was selected as this was the year collation of
the data started and ended. The data collated represented
approximately one-quarter of the total potential dataset available,
as calculated by dividing the total number of small molecules
submitted to the analysis by the total number of small molecules
progressing to FIH start across the participating companies during
the time period 2000e2011.
2.2. Nonclinical data
Eight observations/measurements were selected as being
representative of different neurofunctional clusters: arousal, rear-
ing, vocalization, handling reactivity/aggressiveness, body position
and locomotor activity were included in the behavioral proﬁle
whereas grip strength/traction response and muscle tone, were
part of the neurological proﬁle. These endpoints were chosen since
they could plausibly be aligned with clinical adverse events, and
because the incidence rate for changes in these parameters was
high enough to provide sufﬁcient data for analysis. For parameters/
behaviors that are present under normal conditions, an increase or
decrease was reported and, for parameters/behaviors generally
absent under normal condition “yes” or “no” was recorded. All
outcomes were derived from the conclusions section of the ﬁnal
study report in order to maintain consistency across all companies,
and to avoid re-interpretation of the data.
Effects on food consumption and body weight from equivalent
testing in rodent toxicity studies were also included where avail-
able to provide plausible nonclinical correlates for the FIH AE of
nausea (Parkinson et al., 2012). Equivalent testing was deﬁned as
examination in the same species at the same doses, or a dose which
produced equivalent free plasma drug exposures during the repeat-
dose toxicity study.
2.3. Clinical data
The clinical data from the single ascending dose Phase I study
were collected. This included mean plasma free Cmax at the highest
no-effect dose level in humans if there was no effect and, if there
was an effect, the exposure level at the dose where the effect was
observed and the highest no-effect level. For the purpose of this
study, the effect level was deﬁned as the lowest free plasma drug
exposure at which a clinical AE of interest was observed. The most
common clinical AEs in this dataset were nausea, headache, pain,
somnolence/fatigue, and dizziness. Somnolence and fatigue were
pooled as they might be expected to have similar plausible
nonclinical correlates within the FOB/IT; however it should be
noted that these are classiﬁed differently in the hierarchy of Med-
DRA terminology, and typically denote qualitatively different AE
types. These ﬁve AEs were selected because they had the highest
prevalence (>10%) in the current dataset (Fig. 1). Analysis of other
less common but potentially more impactful AEs was precludeddue to insufﬁcient prevalence of those AEs in the available dataset.
2.4. Deﬁnition of treatment-related AE
Phase I clinical reports may contain AEs in placebo subjects and
spurious AEs sometimes occur at intermediate dose levels. A
treatment-related AE was classiﬁed as such when it occurred either
in the higher exposure group in at least two individuals at a fre-
quency higher than placebo, or in two consecutive dose levels, both
at a higher incidence rate than in the placebo group, occurring in at
least two individuals in at least one of the two consecutive dose
levels. This rule allowed us to qualify the data. While it is recog-
nized that this simpliﬁcation may not be appropriate on an indi-
vidual case basis, it was considered essential when comparing large
datasets with varying numbers of values. It is also similar to the
approach used nonclinically in the FOB/IT.
2.5. Analyses
Two principal analyses were conducted. Firstly a ‘plausible
correlate’ analysis was performed to determine whether the pres-
ence of speciﬁc nonclinical observations predicted the presence of
speciﬁc clinical AEs in the FIH study. The plausible correlates are
shown in Table 2. The correlates represent a consensus opinion of
the contributing authors; it was not possible to deﬁne plausible
correlates for headache in this dataset. Secondly an ‘all AEs overt
toxicity’ analysis was also performed to determine whether the
occurrence of any of the nonclinical ﬁndings predicted the occur-
rence of any of the selected clinical AEs. This was to test whether
the compounds that produce effects in the rodent neurofunctional
assessment involve the same compounds which produce
commonly reported AEs in the FIH study.
2.6. Stratiﬁcation of data
Clinical and nonclinical exposures were compared for each
compound in four bins at 1, 3, 10 and 30 mean clinical Cmax
(where no effect was observed) or the lowest clinical exposure level
(where an effect was observed) in order to understand the impor-
tance of free drug plasma exposure. Cmaxwas chosen in preference
to AUC, since the majority of adverse events analyzed are consid-
ered to relate more directly to acute exposure rather than sustained
exposure. Exposures at which the clinical AEs occurred were then
compared with the nonclinical exposure range to determine
whether an effect was observed within the speciﬁc exposure range.
For example, if a clinical effect was observed at a free drug exposure
of 100 nM, and a nonclinical effect was observed at a free drug
exposure of 600 nM (but no lower), this data point would be
considered a false negative for the 1 and 3 exposure compari-
sons, but a true positive for the 10 and 30 exposure compari-
sons. This analysis allowed for an assessment of the sensitivity of
the neurofunctional endpoints relative to the clinical AEs. The ﬁnal
size of each dataset is the total true positives, true negatives, false
positives and false negatives. Data analysis was also carried out on
the group of compounds that were being developed to target the
CNS compared to those that were not.
2.7. Statistical analysis
Two statistical analyses were performed: (i) a descriptive anal-
ysis summarizing the characteristics of the dataset and the inci-
dence of ﬁndings and (ii) a quantitative analysis based on a
contingency table approach (Coulthard, 2007). The calculations for
each parameter are detailed in Table 3. For each comparison,
compounds were classiﬁed as true positives (TP; compounds found
Fig. 1. Incidence of Clinical AEs within the Dataset. Plots represent the proportion (%) of compounds which produced each clinical AE within the dataset used for this analysis. Panel
A) Proportions of compounds producing the ﬁve most prevalent AEs. Dashed line represents cut-off point for inclusion in analysis (10%). Panel B) proportions of compounds
producing clinical AEs stratiﬁed according to whether compounds were CNS targeted or non-CNS targeted.
Table 2
Plausible Nonclinical Correlates Information in this table represents the plausible nonclinical correlates that were drawn in order to assess translation between the noted
nonclinical ﬁndings and the speciﬁc clinical AEs. No plausible nonclinical correlates could be drawn for the clinical AE of headache.
Clinical AE Nonclinical plausible correlates
Headache None
Nausea Decreased body weight gain or decreased food consumption.
Dizziness Decreased horizontal locomotor activity, decreased rearing (automated) or decreased rearing (observer scored)
Somnolence/
Fatigue
Decreased home cage arousal or decreased grip strength or decreased handling reactivity or increased hunched posture or decreased horizontal activity
(automated) or decreased rearing (automated) or decreased rearing (observer scored)
Pain Decreased horizontal locomotor activity, decreased rearing (automated) or decreased rearing (observer scored) or increased vocalization.
Table 3
Statistical Parameters Used to Determine the Value of Nonclinical Endpoints SENS ¼ Sensitivity, SPEC ¼ Speciﬁcity,
PREV ¼ Prevalence for which PPV or NPV are to be calculated for.
Parameter Formula
Accuracy (TP þ TN)/(TP þ TN þ FP þ FN)
Sensitivity TP/(TP þ FN)
Speciﬁcity TN/(TN þ FP)
Positive Predictive Value (PPV) (SENS*PREV)/(SENS*PREVþ(1-SPEC)*(1-PREV))
Negative Predictive Value (NPV) SPEC*(1-PREV)/(SPEC*(1-PREV)þ(1-SENS)*(PREV))
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sures), true negatives (TN; compounds found to be negative both
the nonclinical and clinical outcome measures), false positives (FP;
compounds found to be positive in the nonclinical but negative in
the clinical outcome measure) or false negatives (FN; compounds
found to be negative in the nonclinical but positive in the clinical
outcome measure). In the analyses presented here, prevalence is
deﬁned as the proportion of clinical studies in which the AE of
interest was observed (TP plus FP). For example, a clinical AE that
was observed in 70 of the 141 studies would have a prevalence of
0.50. The analysis allowed us to statistically evaluate two key
translational concepts, detailed below.2.8. Detection of AEs
The sensitivity and speciﬁcity of the rodent neurofunctional
assessment to detect compounds which produce commonly re-
ported AEs in the FIH study was assessed. Sensitivity represents the
proportion of drugs which produce the clinical event that are
correctly identiﬁed by the nonclinical assessment (TP/TP þ TN).
Speciﬁcity is the proportion of drugs that do not produce the
clinical event and are correctly identiﬁed by the nonclinical
assessment (TN/TN þ FP). This assessment can be visualized byplotting Receiver Operating Characteristic (ROC) curves. A curve
deviating to the upper left from the line of unity represents a test
where the ability to detect effects is better than pre-test probability
(chance).2.9. Prediction of AEs
By evaluating the positive and negative predictive values (PPV
and NPV, respectively), we statistically evaluated the ability of the
rodent neurofunctional assessment to predict the occurrence of
commonly reported AEs in the FIH study. The PPV of a model is the
proportion of compounds with true positive results out of all of the
compounds with positive results in the nonclinical setting, while
the NPV of a model is deﬁned as the proportion of compounds with
true negative results out of all of the compounds with negative
results in the nonclinical setting.
PPV and NPV are inﬂuenced by prevalence. Therefore we
calculated PPV and NPV using both estimated and a range of
prevalence. The observed prevalence is likely to be the actual
prevalence in the dataset because, based on the experience of each
of the contributing authors, the development of compounds is very
rarely stopped based on the ﬁndings from the rodent neurofunc-
tional assessment. The observed prevalence for all of the analyses
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predictive values for all endpoints using an assumed prevalence of
0.1 and 0.4, to roughly capture the range observed. Secondly, where
predictive values deviated from pre-test probability, we recalcu-
lated the PPV and NPV across the full range of prevalence values
(0.1 through to 0.9) to demonstrate that the conclusions were not
reliant on the assumed prevalence values. In this instance, the PPV
and 1-NPV were plotted against prevalence to visualize the
outcome (Rehling, 2010). Using such plots, deviation from the line
of unity (to the upper left for PPV, and to the lower right for 1-NPV)
indicates predictive value of the model above and beyond pre-test
probability (i.e. chance).
To estimate the variance in the data and to assess the conﬁdence
of the statistical estimates utilized in the current review, 95%
conﬁdence intervals (CIs) were calculated for each measure using R
statistical software (version 2.15.2) and in particular, the PropCIs
and pairwise CI libraries, as well as StatXact (Cytel Studio version
8.0.0).
3. Results
3.1. Descriptive analysis
Data comprising 141 small molecule candidate drugs (CDs) were
submitted by ﬁve companies, with each company providing data
for between 2 and 56 CDs. 134/141 (95%) molecules were tested
nonclinically in rat and 7/141 (5%) in mouse, in either the FOB or
Irwin test. Male adult rodents were used for these studies. FIH
studies were carried out in healthy male volunteers for all com-
pounds except two, which had FIH exposure in patient populations.
Of 141 molecules, 87 (62%) molecules were being developed for
non-CNS targets, and 54 (38%) for CNS targets. 109 of the 141
molecules (77%) were shown to elicit commonly reported AEs in
the FIH study, with 49 of these 109 (45%) being CNS-targeted and
60/109 (55%) being non-CNS targeted. Therefore, 49/54 CNS mol-
ecules (90%) and 60/87 (68%) non-CNS targeted molecules elicited
commonly reported AEs in the FIH study. The incidence of the
clinical AEs in this dataset was nausea: 41 (38%), dizziness: 39
(36%), somnolence/fatigue: 35 (33%) and pain: 16 (15%) (Fig. 1).
These ﬁve clinical endpoints were therefore chosen for subsequent
analysis since the prevalence of ﬁndings was considered sufﬁcient
for statistical analysis. The numbers of CDs eliciting AEs outside this
group had an incidence of less than 10%.
The data show that CNS targeted molecules were more likely to
produce commonly reported AEs in the FIH study than non-CNS
targeted molecules (Fig. 1). This difference was more pronounced
with the clinical AEs of dizziness (57% for CNS vs 23% for non-CNS)
and somnolence/fatigue (59% vs 16%) than it was for nausea (48% vs
32%). Furthermore, the clinical AE of painwasmore prevalent in the
non-CNS targeted cohort of molecules (18%) than it was in the CNS
targeted compounds (9%).
3.2. Quantitative analysis
3.2.1. Comparison of plausible nonclinical correlates with FIH AEs
The summary data for each of the nonclinical correlates and the
translation to commonly reported AE incidence are presented in
Table 4. Data were stratiﬁed for each exposure multiple to assess
the effect of plasma free drug exposure on predictive capacity
across rodent and human endpoints. In addition, ROC curves are
plotted for each plausible correlate using sensitivity and speciﬁcity
values at each exposure multiple (Fig. 2).
For the FIH AEs of (i) dizziness (ii) nausea (iii) pain and (iv)
somnolence/fatigue, the ROC curves did not deviate signiﬁcantly
from the line of unity, indicating that the nonclinical correlatesexamined (Table 2) did not provide value in terms of detecting the
occurrence of clinical AEs in the FIH study. Similarly, the PPV and
NPV did not differ signiﬁcantly from pre-test probabilities indi-
cating that the nonclinical correlates examined did not provide
value in predicting the occurrence of dizziness in the FIH study.
These conclusions applied across the range of exposure multiples
examined.
For the FIH AEs of somnolence and fatigue, there was a signiﬁ-
cant deviation from pre-test probability at the 3 exposure mul-
tiple for both PPV and NPV. However, this deviation represented an
inverse relationship (the absence of a change in the nonclinical
outcome predicted the increase presence of fatigue/somnolence).
At the other three exposure multiples, the PPV and NPV did not
deviate signiﬁcantly from pre-test probabilities, indicating that the
nonclinical correlates examined did not provide value in predicting
the occurrence of somnolence/fatigue in the FIH study.
3.2.2. Comparison of overt toxicity (all AEs)
To examine whether the occurrence of any nonclinical ﬁnding
predicted the occurrence of any clinical AE, we also conducted an
overt toxicity comparison using all AEs. This provided an assess-
ment of whether the rodent neurofunctional assessment could
predict any clinical AE, without necessarily predicting a single
speciﬁc clinical AE.
The ROC curve for the overt toxicity (all AEs) analysis did not
deviate signiﬁcantly from the line of unity (Fig. 2) indicating that
the presence of any one of the nonclinical ﬁndings did not provide
any value in detecting the presence of any one of the four clinical
AEs analyzed. Similarly, the PPV and NPV did not differ from pre-
test probabilities, indicating that the nonclinical ﬁndings exam-
ined did not provide value in predicting the occurrence of any of the
studied clinical AEs in the FIH study. These conclusions applied
across all four exposure multiples analyzed.
3.2.3. Stratiﬁcation according to CNS vs non-CNS targeted
molecules
In addition to analyzing the total data set, the data were also
stratiﬁed according to whether the molecule was being developed
to target the CNS or the periphery. The data from this analysis have
not been presented, since the patterns were similar to those
observed with the entire dataset. There was therefore no apparent
difference in the ability of the rodent neurofunctional assessment
to detect or predict commonly reported AEs in FIH studies,
depending on whether the molecules were being targeted to the
CNS or not. One example is presented in Fig. 3, showing similar
patterns for PPV and NPV across the three conditions (total data,
CNS-targeted only and non-CNS targeted only) at the 1 and 3
multiples for the overt toxicity (all AEs) condition. While there was
a qualitative difference at the 1 CNS-only comparison, the large
conﬁdence intervals indicate that this difference may reﬂect the
small sample size for positive nonclinical ﬁndings (n ¼ 8), rather
than a meaningful difference. Indeed, at the 3multiple where the
sample size for positive nonclinical ﬁndings increased to 28, this
dataset looked comparable to the non-CNS targeted subset of
molecules. In general, the overall sample size for CNS-targeted
molecules was smaller than for non-CNS targeted molecules (54
vs 87), resulting in larger conﬁdence intervals in the CNS targeted
analysis.
4. Discussion
The primary purpose of this work was to evaluate the trans-
lational value of the rodent neurofunctional assessment for pre-
dicting the presence of the most commonly reported AEs during
FIH studies. The data (on 141 small molecule CDs from 5
Table 4
Summary Statistics for each Endpoint across the Four Exposure Multiples Data represent values (95% conﬁdence intervals) for each summary measure. FP ¼ False Positive,
TP ¼ True Positive, TN ¼ True Negative, FN ¼ False Negative. Sens ¼ Sensitivity, Spec ¼ Speciﬁcity. PPV¼ Positive Predictive Value, NPV ¼ Negative Predictive Value. Figures in
parentheses following PPV or NPV headings indicate that calculations were performed for assumed actual clinical prevalence of 0.1 or 0.4
All AEs FP TP TN FN Accuracy Sens Spec PPV (0.1) NPV (0.1) PPV (0.4) NPV (0.4)
1 6 15 38 71 0.41 (0.33e0.49) 0.17 (0.11e0.27) 0.86 (0.73e0.94) 0.12 (0.06e0.33) 0.90 (0.89e0.92) 0.46 (0.27e0.74) 0.61 (0.57e0.65)
3 16 27 30 54 0.45 (0.37e0.54) 0.33 (0.24e0.44) 0.65 (0.51e0.77) 0.10 (0.06e0.15) 0.90 (0.87e0.92) 0.39 (0.28e0.52) 0.59 (0.52e0.65)
10 22 37 22 37 0.50 (0.41e0.59) 0.50 (0.39e0.61) 0.50 (0.36e0.64) 0.10 (0.07e0.14) 0.90 (0.86e0.93) 0.40 (0.31e0.50) 0.60 (0.50e0.69)
30 29 43 17 26 0.52 (0.43e0.61) 0.62 (0.51e0.73) 0.37 (0.25e0.51) 0.10 (0.08e0.13) 0.90 (0.84e0.93) 0.40 (0.33e0.47) 0.60 (0.47e0.71)
Dizziness FP TP TN FN Accuracy Sens Spec PPV (0.1) NPV (0.1) PPV (0.4) NPV (0.4)
1 7 2 66 46 0.56 (0.47e0.65) 0.04 (0.01e0.14) 0.90 (0.82e0.95) 0.05 (0.01e0.17) 0.89 (0.88e0.91) 0.22 (0.03e0.55) 0.59 (0.56e0.61)
3 13 4 52 40 0.51 (0.42e0.61) 0.09 (0.04e0.21) 0.80 (0.69e0.88) 0.05 (0.01e0.12) 0.89 (0.87e0.90) 0.23 (0.07e0.45) 0.57 (0.53e0.61)
10 16 7 36 31 0.48 (0.38e0.58) 0.18 (0.09e0.33) 0.69 (0.56e0.80) 0.06 (0.02e0.13) 0.88 (0.86e0.91) 0.29 (0.13e0.46) 0.56 (0.50e0.62)
30 16 12 23 23 0.47 (0.36e0.59) 0.34 (0.21e0.51) 0.59 (0.43e0.73) 0.08 (0.05e0.14) 0.89 (0.85e0.92) 0.36 (0.22e0.55) 0.57 (0.48e0.66)
Nausea FP TP TN FN Accuracy Sens Spec PPV (0.1) NPV (0.1) PPV (0.4) NPV (0.4)
1 5 4 60 48 0.55 (0.46e0.63) 0.08 (0.03e0.18) 0.92 (0.83e0.97) 0.10 (0.02e0.31) 0.90 (0.89e0.91) 0.40 (0.13e0.73) 0.60 (0.57e0.63)
3 12 6 50 38 0.53 (0.43e0.62) 0.14 (0.06e0.27) 0.81 (0.69e0.89) 0.07 (0.03e0.16) 0.89 (0.87e0.91) 0.32 (0.13e0.53) 0.58 (0.54e0.63)
10 17 13 40 33 0.51 (0.42e0.61) 0.28 (0.17e0.43) 0.70 (0.57e0.80) 0.10 (0.05e0.16) 0.90 (0.87e0.92) 0.39 (0.24e0.54) 0.59 (0.53e0.66)
30 22 20 24 17 0.53 (0.42e0.63) 0.54 (0.38e0.69) 0.52 (0.38e0.66) 0.11 (0.07e0.16) 0.91 (0.87e0.94) 0.43 (0.33e0.54) 0.63 (0.52e0.73)
Pain FP TP TN FN Accuracy Sens Spec PPV (0.1) NPV (0.1) PPV (0.4) NPV (0.4)
1 9 2 93 17 0.79 (0.70e0.85) 0.11 (0.03e0.31) 0.91 (0.84e0.95) 0.12 (0.01e0.33) 0.90 (0.89e0.92) 0.44 (0.06e0.75) 0.60 (0.57e0.67)
3 18 4 73 14 0.71 (0.62e0.78) 0.22 (0.09e0.45) 0.80 (0.71e0.87) 0.11 (0.03e0.23) 0.90 (0.88e0.93) 0.43 (0.16e0.64) 0.61 (0.55e0.69)
10 29 3 47 13 0.54 (0.44e0.64) 0.19 (0.07e0.43) 0.62 (0.51e0.72) 0.05 (0.01e0.12) 0.87 (0.84e0.91) 0.25 (0.07e0.45) 0.53 (0.46e0.63)
30 29 4 31 10 0.47 (0.36e0.59) 0.29 (0.12e0.55) 0.52 (0.39e0.64) 0.06 (0.02e0.12) 0.87 (0.82e0.92) 0.28 (0.11e0.46) 0.52 (0.43e0.65)
Fatigue FP TP TN FN Accuracy Sens Spec PPV (0.1) NPV (0.1) PPV (0.4) NPV (0.4)
1 9 4 70 40 0.60 (0.51e0.68) 0.09 (0.04e0.21) 0.89 (0.80e0.94) 0.08 (0.01e0.21) 0.90 (0.89e0.91) 0.35 (0.08e0.62) 0.59 (0.56e0.63)
3 18 4 52 40 0.49 (0.40e0.58) 0.09 (0.04e0.21) 0.74 (0.63e0.83) 0.04 (0.01e0.09) 0.88 (0.86e0.90) 0.19 (0.05e0.38) 0.55 (0.50e0.59)
10 23 13 36 30 0.48 (0.39e0.58) 0.30 (0.19e0.45) 0.61 (0.48e0.72) 0.08 (0.04e0.13) 0.89 (0.85e0.91) 0.34 (0.22e0.47) 0.57 (0.49e0.64)
30 26 19 26 20 0.49 (0.39e0.60) 0.49 (0.34e0.64) 0.50 (0.37e0.63) 0.10 (0.06e0.14) 0.90 (0.85e0.93) 0.39 (0.29e0.59) 0.59 (0.49e0.69)
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analysis methods to evaluate the predictive validity. First, a plau-
sible association analysis was conducted to determine whether a-
priori assumptions on prediction were valid. Second, an overt
toxicity (all AEs) analysis was conducted to understand whether
nonclinical testing identiﬁed those compounds which were more
likely to result in commonly reported AEs in the FIH study,
regardless of the speciﬁc nature of the nonclinical or clinical events.
Sensitivity/speciﬁcity and predictive value analyses were used
to evaluate the ability of the nonclinical model to detect and predict
compounds which would produce a clinical effect. Our data indi-
cate the rodent neurofunctional assessment provides no signiﬁcant
value in detecting or predicting the presence of the most commonly
reported AEs in the FIH study. The selected AEs were considered to
represent CNS-related events, with recognition that etiology may
not be mediated directly within the CNS. For example, while the
perception of nausea or pain requires the CNS, the cause of these
AEs may be a direct effect on the gastrointestinal system or pe-
riphery. Furthermore, MedDRA classiﬁcation of these AEs falls
across multiple system organ classes. Pain and fatigue are classiﬁed
under “General Disorders and Administration Site Conditions”,
nausea is classiﬁed under “Gastrointestinal disorders” whereas
somnolence, headache and dizziness are classiﬁed under “Neuro-
logical disorders”.
It is important to note that the most common AEs are not
necessarily the most serious AEs. Compounds that cause more se-
vere AEs such as convulsions or ataxia may have already been
detected in other nonclinical studies prior to the regulatory FOB/IT
study, and deselected for development. Depending on their
severity, nausea, dizziness, somnolence/fatigue and pain may not
always be dose limiting or impactful on drug development, but may
contribute to an unfavorable side effect proﬁle.
In addition, the FOB/IT have been validated against known CNS-
modulating agents, and the assays are sensitive for those less
common but potentiallymore serious AEs (Baird et al., 1997; de Ronet al, 2015; Ewart et al., 2014; Igarashi et al., 1995; Irwin, 1968;
Moscardo et al., 2007; Redfern et al. 2002, 2005). Agents produc-
ing less serious AEs such as nausea, dizziness and pain have not
been used to validate the FOB/IT.
4.1. Plausible correlates
The lack of translation between ‘plausible correlates’ may not be
particularly surprising. It may be that the prediction of speciﬁc
commonly reported AEs requires a more considered and targeted
approach. Previous publications have noted that drug-induced
adverse effects such as headache are not easy to predict in
nonclinical species (Redfern et al., 2002). In the case of nausea,
physiological differences between species result in differences in
the manifestation of nausea. Nausea may be predicted from a
compilation of nonclinical data using an algorithm (Holmes et al.,
2009; Parkinson et al., 2012), which can be used to trigger spe-
ciﬁc in-vivo investigations such as the pica model of nausea in rats
(Liu et al., 2005).
The plausible association analysis was restricted to measures
that the authors expected to have the greatest likelihood of pre-
dictive value. Choice of other endpoints or combinations of end-
points, both nonclinically and clinically, may improve translation. It
is also worth noting that the Irwin/FOB allows a close-up, sys-
tematic evaluation of a range of nervous system functions which
enables the detection of abnormal behaviors (e.g. abnormal
posture; unsteady gait; tremor; orofacial dyskinesias) and auto-
nomic changes (e.g. mydriasis). However, these are not featured in
our current analysis as the human equivalent effects were of too
low a frequency in our dataset to enable statistical analysis.
4.2. Exposure range
The predictive value of the neurofunctional assessment was not
inﬂuenced by the exposure range over which effects were
Fig. 2. Receiver Operating Characteristic (ROC) Curves for Each Clinical AE. Plots represent sensitivity and 1-speciﬁcity across the four exposure multiples examined (1, 3, 10
and 30), and 95% conﬁdence intervals (CIs). Dashed line indicates line of unity, indicating test performance with no value in detecting effects. Points above and to the left of this
line represent test performance value for detecting effects.
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from 1 through to 30, and in all instances the neurofunctional
assessment provided no signiﬁcant value in determining the
presence of commonly reported AEs in the FIH study. This analysis
suggests that the lack of translation cannot simply be attributed to
compounds achieving different exposures in the two species.4.3. Clinical prevalence
One of the challenges with evaluating the predictive value of
tests concerns the importance of understanding the clinical prev-
alence of an endpoint across studies when interpreting the sum-
mary statistics (see (Coulthard, 2007) for a review on this topic). To
address this, we took two approaches. First, we attempted to un-
derstand the actual prevalence of the clinical AEs studied from the
contributing pharmaceutical companies. Across the companies that
contributed data to this analysis, results from the pre-FIH rodent
neurofunctional assessment have rarely led to the development of a
compound being stopped, because highly toxic agents are often
eliminated during early-stage or exploratory toxicity studies, and
do not progress to CNS safety pharmacology core-battery testing.
As a result, it is not unreasonable to assume that the observed
prevalence across the dataset within the analysis reﬂects the likely
actual prevalence for clinical positives. To assess the inﬂuence of
prevalence on the dataset, we also calculated predictive valuesacross the entire range of potential prevalence values (0.1 through
to 0.9) for one example (Fig. 3, All AEs at the 1 and 3 exposure
multiples). This example clearly shows that while prevalence across
the dataset impacts the overall magnitude of the predictive value,
the signiﬁcance of the effect and therefore the qualitative deter-
mination of test value does not change.4.4. CNS vs non-CNS targeted compounds
We investigated whether the predictive value of the model was
inﬂuenced by CNS and non-CNS targeted compounds. There were
no differences in the conclusions based on whether the compound
was in development for a CNS or a non-CNS indication. The hy-
pothesis behind this analysis was that compounds developed for
CNS indications would be more likely to be CNS penetrant and
therefore more likely to induce the commonly reported AEs of
dizziness and somnolence in the FIH study through a direct
mechanism. There are two potential explanations for not observing
this predicted effect. First, many compounds developed to act
peripherally are still likely to cross the blood brain barrier at a
sufﬁcient level of penetration to produce CNS pharmacodynamic
effects. However, this explanation is unlikely to fully explain the
lack of effect, since the proportion of CNS targeted compounds
producing AEs in the FIH studies was greater than the proportion
seenwith non-CNS targeted compounds (90% vs. 68%). Others have
Fig. 3. Examining Predictive Value over the Full Range of Potential Clinical Prevalence Values. Plots show positive predictive value (PPV) and negative predictive value (NPV), and
95% conﬁdence intervals across the full range of prevalence values. Examples shown are for the data from the All AEs analysis at the 1 (panels A-C) and the 3 (panels D-F)
exposure multiples. Deviation from the line of unity (dashed line) indicates predictive value of the test, with the displayed conﬁdence intervals. In this example, data is shown for
the total data set (panels A and D), for data where compounds were targeted to the CNS (panels B and E) and for compounds where speciﬁcally not targeted to the CNS (panels C and
F).
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related side effects linked to the target pharmacology (Cook et al.,
2014). Second, the clinical adverse events assessed in this analysis
may not necessarily reﬂect a direct central mechanism of action.
The conclusion from this analysis is that stratiﬁcation by central
targeting vs. non-central targeting does not alter the predictive
value of the rodent neurofunctional assessment, with regards to the
occurrence of common AEs in FIH studies.
4.5. Data interpretation and context
It is important that the data described are interpreted, consid-
ered and applied appropriately within the context of this analysis,
and not over-interpreted by generalisation or spurious application
of these results to other datasets. Furthermore the conclusions from
this analysis should not be broadly generalized to translational
questions from rodent to man in the ﬁeld of CNS neuropharma-
cology. The value of any analysis is restricted to the nature of the
data upon which it is based (Hendrie et al., 2013). Within this
analysis, efforts were taken to ensure a relatively unbiased selec-
tion of data. The submitted data represents approximately one-
quarter of the available study data from each company and com-
prises a broad selection of compounds from different classes, with
different physicochemical and pharmacokinetic properties, fordifferent indications. By selecting compounds across a diverse
range of chemical classes, we believe that this risk has been miti-
gated as effectively as possible. Finally, it is important to recognize
that the compounds that were included in this analysis necessarily
represent those compounds considered safe to progress to FIH
studies, and may not truly represent the broader chemical and/or
pharmacological diversity that may be available earlier in the drug
discovery process. However, as the learnings from this analysis
should only ever be applied to the same stage of drug development,
this is not a signiﬁcant limitation.
In order to explore the translation of other speciﬁc CNS-related
AEs, future analyses may beneﬁt from a much larger dataset con-
taining a higher incidence of less common CNS-related AEs such as
ataxia, tremor, insomnia, and autonomic effects. These AEs are
considered to be within the intended scope of the nonclinical
neurobehavioural assessments (FOB/Irwin test). Low or no preva-
lence of these ﬁndings in this dataset precluded this analysis, which
was a limitation of this study.
To overcome some of the limitations described in this paper and
improve the ability to analyse clinical adverse events, future studies
could i) compare assessments of arousal/alertness/activity in the
FOB/Irwin test with measurement of spontaneous locomotor ac-
tivity, ii) collect a larger dataset and iii) consider augmenting ﬁrst in
human assessments to assess more than just tolerability.
Table 5
Publications providing evidence of good translation from rat FOB/Irwin to human for effects related to ‘somnolence’ or ‘fatigue’.
Drug causing ‘somnolence’ in humans Related effect in rat FOB/Irwin Reference
Ethanol Decreased arousal, handling reactivity and activity; ataxia Bowen et al., 1996
Chlorpromazine Decreased activity; reduced startle response (etc.) Mattson et al., 1996; Redfern et al., 2005;
Moscardo et al., 2007
Diazepam Decreased arousal and touch response Moscardo et al., 2007
Clonidine Sedation; ptosis Moscardo et al., 2007; Ewart et al., 2013
A.N. Mead et al. / Regulatory Toxicology and Pharmacology 80 (2016) 348e357356Spontaneous motor activity measured in the homecage environ-
ment may also reduce stress induced by being moved to a novel
environment.
4.6. Why was somnolence/fatigue not predicted nonclinically?
The expected correlation of decreased activity, reduced reac-
tivity or decreasedmuscle tone in animals with somnolence/fatigue
in humans is based on the pharmacological validation of these
models using classical sedative drugs such as chlorpromazine,
clonidine and the benzodiazepine or barbiturate classes (Table 5).
However, it is important to note that these compounds produce a
broad spectrum of CNS depressant effects. For CDs that possess a
more speciﬁc or subtle action, effects on motor function and reac-
tivity may not always occur concurrently with effects on sleep or
weakness and lethargy. Therefore, the prediction of sedation or
fatigue may be better served through locomotor activity mea-
surements (Patterson et al., 2005; Lynch et al., 2011), 24 h home
cage activity monitoring (Leslie et al., 2015), high resolution
accelerometry (Venkatraman et al., 2010), quantitative electroen-
cephalography (Bassett et al., 2014) or the assessment of sleep
states in animals using polysomnography (Ivarsson et al., 2005).
Additionally, we pooled the clinical AEs of somnolence and fatigue
as we felt the nonclinical effects with a plausible correlation to
these would be the same (or very similar); possibly this impacted
on the translational analysis.
4.7. Development of predictive models
Assessing the predictive value of other models which better
predict clinical AEs is an obvious area of future research, especially
for those AEs which are considered most prohibitive in terms of
drug development. In order to understand the technical and sta-
tistical performance of the animal test against compounds with
known outcome in clinical use, a large data set balanced for prev-
alence is required. This would allow analysis of the overall preva-
lence across the industry, and would provide researchers with
information on the ability of a model to predict the presence or
absence of an AE in clinical use. Such an undertaking would require
unprecedented collaboration across the pharmaceutical industry
and access to full datasets.
It will be important to also compare the translational value of
nonclinical data from rodent FOB/Irwin models with repeat-dose
toxicity studies, ‘lower’ and ‘higher’ order alternative species or
in-silico/in-vitro models. It will be important to assess whether
alternative approaches could potentially provide equivalent value
with less resource and greater adherence to the 3Rs principles
(EMA, 2014; Pugsley et al., 2014). The authors recommend caution
in the general assumption that introducing large animal species
such as dog or non-human primate will provide better translation
and reduce attrition, without a strong evidence base.
5. Conclusions
In summary, the analysis reported here demonstrates that, inthe context of the methods applied in this analysis, the rodent
neurofunctional assessment does not detect or predict the most
commonly observed AEs in FIH studies, namely nausea, headache,
dizziness, somnolence/fatigue, or pain. The presence of any ﬁnding
in the rodent neurofunctional assessment does not predict the
likelihood of whether compounds will produce any of the most
common AEs during the FIH study. A larger dataset containing a
higher number of compounds and representing a broader range of
AEs would allow further analysis of the predictive nature of the
FOB/IT.
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